Revive Therapeutics Ltd. has completed Phase II-A clinical studies for its gout treatment candidate, REV-002, a significant step forward in its mission to provide innovative solutions in the healthcare sector.

Revive Therapeutics Ltd. is a Canadian company pioneering cannabinoid-based treatments, with a notable achievement in completing Phase II-A clinical studies for its gout treatment product, REV-002.